When are aminoglycosides indicated, and what are the recommended dosing, monitoring, and duration guidelines for serious Gram‑negative infections?

Aminoglycosides for Serious Gram-Negative Infections

For serious Gram-negative infections including sepsis and septic shock, aminoglycosides should be dosed at 5–7 mg/kg (gentamicin/tobramycin equivalent) or 15–20 mg/kg (amikacin) once daily in patients with preserved renal function, with therapeutic drug monitoring focused on ensuring low trough concentrations to minimize nephrotoxicity. 1

Indications for Aminoglycosides

Aminoglycosides are indicated in the following clinical scenarios:

• Severe sepsis and septic shock: Use in combination with broad-spectrum β-lactam antibiotics for empiric coverage of Gram-negative pathogens, particularly when multidrug-resistant organisms are suspected 1
• Gram-negative bacteremia and nosocomial pneumonia: Especially when caused by multidrug-resistant Enterobacterales or Pseudomonas aeruginosa 1
• Complicated urinary tract infections (cUTI): For short-duration therapy when the organism is susceptible, particularly in patients without septic shock 2
• Carbapenem-resistant Enterobacterales (CRE) infections: As part of combination therapy when other options are limited 2, 3
• Extended-spectrum β-lactamase (ESBL)-producing Enterobacterales: Amikacin is generally more active than other aminoglycosides against ESBL-producing and quinolone-resistant E. coli 4

Optimal Dosing Strategy

Standard Dosing in Preserved Renal Function

Once-daily extended-interval dosing is the preferred approach because it optimizes peak drug concentrations, yields comparable or superior clinical efficacy, and reduces nephrotoxicity compared to multiple daily dosing 1, 5, 1, 5:

• Gentamicin or tobramycin: 5–7 mg/kg once daily 1, 5, 1, 5
• Amikacin: 15–20 mg/kg once daily 6, 7

Critical Considerations for Critically Ill Patients

Critically ill patients with sepsis require special attention to initial dosing due to increased volume of distribution from aggressive fluid resuscitation 1:

• Always initiate with a full, high-end loading dose regardless of renal function 1
• The loading dose is not affected by renal dysfunction, though subsequent dosing intervals may need adjustment 1
• In surgical ICU patients, higher doses (gentamicin/tobramycin 5 mg/kg, amikacin 20 mg/kg) may be needed to achieve adequate peak concentrations due to volume of distribution averaging 0.50 L/kg 7

Dosing in Renal Impairment

• Mild chronic renal impairment: Administer the full once-daily equivalent dose but extend the interval between doses (up to 3 days) 1, 5, 1, 5
• Severe renal dysfunction: Do not use once-daily dosing if the aminoglycoside is not expected to clear within several days 1, 5, 1, 5

Pharmacodynamic Targets

Clinical success correlates with achieving high peak blood levels relative to pathogen MIC 1:

• Target peak concentration (Cmax) to MIC ratio ≥8–10 for optimal bacterial killing 8, 9
• Target AUC of 100 mg·h/L over 24 hours 8
• Failure to achieve adequate peak plasma targets on initial dosing is associated with clinical failure 1

Therapeutic Drug Monitoring (TDM)

TDM should be performed when possible, particularly for narrow therapeutic index drugs like aminoglycosides 3:

• Primary purpose: Ensure trough concentrations are sufficiently low to minimize renal toxicity 1, 5, 1, 5
• When to monitor: Especially important when high doses are administered, in patients with renal dysfunction, or during prolonged therapy 3
• Recommended in: Severe infections (bloodstream infections, sepsis), central nervous system infections, and patients with organ dysfunction 3

Duration of Therapy

Aminoglycoside therapy should be limited to short durations to minimize toxicity:

• For intra-abdominal infections with adequate source control: 4–7 days 6
• For cUTI: Short-duration therapy when active in vitro 2
• Avoid prolonged dosing cycles to reduce ototoxicity risk 10
• Consider de-escalation or transition to oral therapy once clinical improvement occurs and susceptibility results are available 2

Combination Therapy Considerations

Aminoglycosides are typically used in combination rather than as monotherapy for serious infections:

• Combine with broad-spectrum β-lactams for empiric therapy of sepsis/septic shock 1
• For CRE infections, aminoglycoside-containing combination therapy may improve cure rates and reduce mortality 3
• Synergistic effects occur when combined with β-lactams against Gram-negative pathogens 4, 8

Common Pitfalls and Safety Considerations

Nephrotoxicity Prevention

• Avoid concomitant nephrotoxic drugs when possible (e.g., vancomycin, NSAIDs, contrast agents) 3
• Once-daily dosing provides a longer time until the nephrotoxicity threshold is reached compared to multiple daily dosing 8
• Monitor renal function before and during treatment 4

Ototoxicity Prevention

• Avoid use in patients with the m.1555 A>G gene variant, which significantly increases ototoxicity risk 10
• No dosing regimen appears less ototoxic than another 8
• Perform audiometry assessment before and after treatment when feasible 4

Dosing Errors to Avoid

• Do not underdose the initial loading dose in critically ill patients—this is associated with clinical failure 1
• Do not adjust the loading dose for renal dysfunction—only subsequent doses and intervals require adjustment 1
• In obese patients, use adjusted body weight for dosing calculations 6

Special Populations

Pregnancy

• For severe tularemia infections in pregnant patients, consider treating initially with an aminoglycoside if possible 11
• Some experts recommend conventional dosing rather than extended-interval dosing in pregnancy 11

Neonates

• For complicated intra-abdominal infections: ampicillin, gentamicin, and metronidazole is an appropriate regimen 6

Agent Selection

Choose aminoglycoside based on local resistance patterns and specific pathogen susceptibility 4:

• Amikacin: Generally more active against ESBL-producing and quinolone-resistant E. coli than other aminoglycosides; preferred for multidrug-resistant Enterobacterales 4
• Gentamicin or tobramycin: Appropriate for most susceptible Gram-negative infections 1
• Local drug committees should decide on first-line aminoglycoside based on institutional resistance data 4